Stroke Research and Treatment / 2018 / Article / Tab 4

Clinical Study

Longitudinal Study on Low-Dose Aspirin versus Placebo Administration in Silent Brain Infarcts: The Silence Study

Table 4

Number and rates of secondary endpoints, tolerability and drop out occurrences during the trial.

ASA n=36controls n=47

n (%)n (%)
Primary endpoint2 (5.6)9 (19.1)
Other cardiovascular events2 (5.6)1 (2.1)
Adverse events2 (5.6)2 (4.2)
Switch ASA-2 (4.2)
Lost to follow-up9 (25.0)9 (19.1)
Mortality-1 (2.1)
Low compliance2 (5.6)-
Withdraws consent4 (11.1)-

Completed follow-up15 (41.7)23 (48.9)

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.